P-I-P pre-treatment, consisting of poly(I:C), IDR peptide and PCEP, was tested in the context of PVM infection in mice.

P-I-P confers complete protection against lethal PVM infection by reducing clinical signs and immunopathology.

P-I-P minimizes viral titers in the lungs reduces the influx of neutrophils and eosinophils into the tissue.

P-I-P induces early upregulation of genes involved in host defense without any observable adverse effects.

Survivor mice were PVM negative, suggesting that P-I-P mediates the successfully clearance of the virus in vivo.